EU HTA Lead

July 16, 2024 By Ruairi O'Donnell, PhD Interview with Ruairi O'Donnell EU HTA Lead at Cencora In this interview, Ruairi O'Donnell, EU HTA Lead at Cencora, delves into the intricacies of the Joint Clinical Assessment (JCA) process and its impact on health technology developers (HTDs), particularly concerning the challenges of predicting and addressing PICOs (Population, Intervention, Comparator, Outcome). What is the scoping process in the JCA and why is it important?

May 8, 2024 By Mareike Konstanski, MSc, Susanne Kossow, PhD, Ruairi O'Donnell, PhD, Kim Joline Schmidt, MSc Less than one year before the implementation of the European Union Health Technology Assessment Regulation (EU HTAR), industry and national HTA bodies are still missing clarity on the Joint Scientific Consultation (JSC) and Joint Clinical Assessment (JCA) procedures. The first implementing act of JCA has now been published, but does it address the stakeholders’ concerns?

March 13, 2024 By Ruairi O'Donnell, PhD 5-minute read One such example is the creation of a new Center of Excellence focused on European Health Technology Assessment (HTA). As part of this initiative, we sat down with our new EU HTA lead, Ruairi O’Donnell, to discuss the importance of the role and what he hopes to achieve in the coming years.